Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Accumulated Expenses (2019 - 2024)

Historic Other Accumulated Expenses for Allogene Therapeutics (ALLO) over the last 6 years, with Q4 2024 value amounting to $1.1 million.

  • Allogene Therapeutics' Other Accumulated Expenses fell 4074.07% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.1 million, marking a year-over-year decrease of 4074.07%. This contributed to the annual value of $1.1 million for FY2024, which is 4074.07% down from last year.
  • Latest data reveals that Allogene Therapeutics reported Other Accumulated Expenses of $1.1 million as of Q4 2024, which was down 4074.07% from $1.8 million recorded in Q4 2023.
  • Over the past 5 years, Allogene Therapeutics' Other Accumulated Expenses peaked at $4.8 million during Q4 2020, and registered a low of $1.1 million during Q4 2024.
  • In the last 5 years, Allogene Therapeutics' Other Accumulated Expenses had a median value of $1.8 million in 2023 and averaged $2.3 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 5874.75% in 2020, then crashed by 6357.75% in 2021.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Other Accumulated Expenses stood at $4.8 million in 2020, then tumbled by 63.58% to $1.7 million in 2021, then increased by 21.38% to $2.1 million in 2022, then fell by 14.59% to $1.8 million in 2023, then plummeted by 40.74% to $1.1 million in 2024.
  • Its last three reported values are $1.1 million in Q4 2024, $1.8 million for Q4 2023, and $2.1 million during Q4 2022.